We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Phibro Animal Health Is Worth Buying Right Now
Read MoreHide Full Article
Phibro Animal Health Corporation (PAHC - Free Report) , headquartered in New Jersey, is a leading global diversified animal health and mineral nutrition company. It has rallied 24.2% over the past three months, ahead of the S&P 500’s mere 2.6% gain. The stock has a market cap of $1.4 billion.
Also over this period, the company’s share price has outperformed the Zacks categorized Medical - Products sub-industry’s gain of 6.1%. With solid growth prospects, this Zacks Rank #2 (Buy) stock is an attractive pick at present.
Phibro’s Animal Health segment continues to be the key contributing business. It currently provides Medicated Feed Additives (MFA) products with the potential to capture a large share of the huge and growing global animal health market. Management believes that the company is well-positioned in the fastest growing food segment of the animal health market with a diversified product portfolio.
Outside the U.S., Phibro’s global footprint extends to Brazil and other countries in South America, China, India and Asia Pacific, Russia and Africa. The company has continued to invest in the Far East Asia where the poultry and dairy industries are expected to grow exponentially.
Currently, the company is expanding the dairy business in the markets of Australia, Brazil and Mexico. We believe that despite the turmoil in the economies of Russia, Greece, Brazil and China, Phibro has performed quite well and has the potential to maintain that healthy momentum.
Meanwhile, the company is progressing well with vaccine business. In the last reported first quarter of 2017, sales from vaccines increased 30%, principally on volume growth of the company’s products for poultry and swine industries.
Earlier, Phibro had become the exclusive distributor of MJ Biologics, Inc. (MJB) that works on research and development of animal health products. This represents the company’s foray into the swine vaccine market. Both firms are working on developing certain animal vaccines. So far, the collaboration has helped expand Phibro’s U.S. swine product offering to include specialized vaccines.
Align Technology has an expected long-term adjusted earnings growth of almost 24.1%. The stock has roughly added 30.9% over the last three months.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has a solid one-year return of around 88%.
Accelerate Diagnostics has an expected long-term adjusted earnings growth of 30%. The stock has approximately added 20% over the last three months.
3 Stocks to Ride a 588% Revenue Explosion
At Zacks, we're mostly focused on short-term profit cycles, but the hottest of all technology mega-trends is starting to take hold...
By last year, it was already generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. See Zacks' Top 3 Stocks to Ride This Space >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Here's Why Phibro Animal Health Is Worth Buying Right Now
Phibro Animal Health Corporation (PAHC - Free Report) , headquartered in New Jersey, is a leading global diversified animal health and mineral nutrition company. It has rallied 24.2% over the past three months, ahead of the S&P 500’s mere 2.6% gain. The stock has a market cap of $1.4 billion.
Also over this period, the company’s share price has outperformed the Zacks categorized Medical - Products sub-industry’s gain of 6.1%. With solid growth prospects, this Zacks Rank #2 (Buy) stock is an attractive pick at present.
Phibro’s Animal Health segment continues to be the key contributing business. It currently provides Medicated Feed Additives (MFA) products with the potential to capture a large share of the huge and growing global animal health market. Management believes that the company is well-positioned in the fastest growing food segment of the animal health market with a diversified product portfolio.
Outside the U.S., Phibro’s global footprint extends to Brazil and other countries in South America, China, India and Asia Pacific, Russia and Africa. The company has continued to invest in the Far East Asia where the poultry and dairy industries are expected to grow exponentially.
Currently, the company is expanding the dairy business in the markets of Australia, Brazil and Mexico. We believe that despite the turmoil in the economies of Russia, Greece, Brazil and China, Phibro has performed quite well and has the potential to maintain that healthy momentum.
Meanwhile, the company is progressing well with vaccine business. In the last reported first quarter of 2017, sales from vaccines increased 30%, principally on volume growth of the company’s products for poultry and swine industries.
Earlier, Phibro had become the exclusive distributor of MJ Biologics, Inc. (MJB) that works on research and development of animal health products. This represents the company’s foray into the swine vaccine market. Both firms are working on developing certain animal vaccines. So far, the collaboration has helped expand Phibro’s U.S. swine product offering to include specialized vaccines.
Key Picks
Other top-ranked medical stocks are Align Technology, Inc. (ALGN - Free Report) , Inogen, Inc. (INGN - Free Report) and Accelerate Diagnostics, Inc. (AXDX - Free Report) . Align Technology and Inogen sport a Zacks Rank #1 (Strong Buy), while Accelerate Diagnostics carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technology has an expected long-term adjusted earnings growth of almost 24.1%. The stock has roughly added 30.9% over the last three months.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has a solid one-year return of around 88%.
Accelerate Diagnostics has an expected long-term adjusted earnings growth of 30%. The stock has approximately added 20% over the last three months.
3 Stocks to Ride a 588% Revenue Explosion
At Zacks, we're mostly focused on short-term profit cycles, but the hottest of all technology mega-trends is starting to take hold...
By last year, it was already generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. See Zacks' Top 3 Stocks to Ride This Space >>